Price$3.51-1.15 (-24.68%)
2026-03-092026-06-10
News · 26 weeks54-50%
2025-12-142026-06-07
Mix3390d
- Insider19(58%)
- Other7(21%)
- SEC Filings5(15%)
- Earnings1(3%)
- Offering1(3%)
Latest news
25 items- PRTriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver CancerNewly published study demonstrates 48% improvement in drug delivery with PEDD™; sicker patients experienced fewer adverse events, 61% reduced hospital readmissions. Leading interventional oncologist to share clinical experience and patient case examples TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly published real-world outcomes study demonstrating th
- SECAmendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.SCHEDULE 13G/A - TriSalus Life Sciences, Inc. (0001826667) (Subject)
- INSIDERChief Commercial Officer Marshak Richard sold $1,450 worth of shares (543 units at $2.67), decreasing direct ownership by 0.43% to 125,101 units (SEC Form 4) to cover withholding tax4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Stansky Michael P bought $1,525,000 worth of shares (610,000 units at $2.50), increasing direct ownership by 49% to 1,240,722 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERChief Financial Officer Patience David bought $17,253 worth of shares (7,100 units at $2.43), increasing direct ownership by 3% to 275,757 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERCEO and President Szela Mary T bought $102,776 worth of shares (39,682 units at $2.59), increasing direct ownership by 4% to 1,065,215 units (SEC Form 4) to cover withholding tax4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Gordon Gary B. bought $24,600 worth of shares (10,000 units at $2.46), increasing direct ownership by 16% to 72,510 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- SECSEC Form SCHEDULE 13G filed by TriSalus Life Sciences Inc.SCHEDULE 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)
- INSIDERDirector Gordon Gary B. was granted 52,754 shares, increasing direct ownership by 541% to 62,510 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Hicks Kerry R was granted 28,201 shares, increasing direct ownership by 5% to 542,790 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Wahlstrom Mats was granted 71,828 shares, increasing direct ownership by 457% to 87,555 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Stansky Michael P was granted 43,590 shares, increasing direct ownership by 6% to 830,722 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Valle William was granted 52,754 shares, increasing direct ownership by 173% to 83,241 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- INSIDERDirector Matlin David J was granted 51,266 shares, increasing direct ownership by 4% to 1,323,210 units (SEC Form 4)4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- SECTriSalus Life Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- SECSEC Form 10-Q filed by TriSalus Life Sciences Inc.10-Q - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- SECTriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- PRTriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term GrowthGenerated first quarter revenue of $8.9 million and expanded commercial organization to support future growth and broader market penetration Published landmark, real-world PEDD® Study of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance despite greater baseline clinical complexity Presented new clinical and preclinical PEDD data across multiple oncology and embolization applications at the 2026 Society of Interventional Radiology Annual Scientific Meeting Strengthened balance sheet with $46 million equity raise; cash balance of $
- PRReal-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge AvoidanceStudy of 603 PEDD patients and 16,210 non-PEDD patients found PEDD technology was associated with fewer post-procedure complications, reduced hospitalizations, and approximately $7,700 in per-patient charge avoidance despite greater baseline clinical complexity TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery (PEDD®) technology used in t
- PRTriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver TumorsTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the initiation of patient enrollment for the PREDICTT clinical trial (NCT07444645), a prospective study designed to evaluate its novel Pressure-Enabled Drug Delivery™ (PEDD™) approach in patients with primary or metastatic liver tumors. The PREDICTT trial is an investigator-led single-arm, prospective, interventional study designed to evaluate how PEDD impacts tumor targeting and radiation dose distribution. Investigators at The
- SECTriSalus Life Sciences Inc. filed SEC Form 8-K: Leadership Update8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)
- PRTriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference CallConference Call and Webcast Scheduled for Tuesday, May 12, 2026 at 4:30 PM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended March 31, 2026. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the call,
- INSIDERSEC Form 4 filed by Frankenius Equity Ab4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)
- PRTriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific MeetingTriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced its participation in the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Ontario, Canada. TriSalus will showcase new clinical and preclinical data highlighting the capabilities of its Pressure Enabled Drug Delivery™ (PEDD™) platform to enhance therapeutic delivery across multiple disease states. Featured presentations include: April 13, 2026 | 12:10 PM ET
TLSI FAQ
6 questionsWhere does TLSI stock trade?
TriSalus Life Sciences Inc. (TLSI) is listed on NASDAQ.What sector and industry is TLSI in?
TriSalus Life Sciences Inc. operates in the Health Care sector, Medical Specialities industry.When did TriSalus Life Sciences Inc. go public?
TriSalus Life Sciences Inc. (TLSI) completed its IPO in 2021.What are analysts saying about TLSI?
TriSalus Life Sciences Inc. has had 6 recent analyst actions on file. The most recent action was from Lake Street: Buy on 2025-02-13. Recent price targets range from $1000.00 to $1250.00.What companies are similar to TLSI?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare TLSI side-by-side with any of them on Quantisnow.How can I track TLSI on Quantisnow?
Quantisnow aggregates TriSalus Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TLSI to receive live email and push alerts on every new disclosure.